Dose-Escalation Phase 1 Study of G-202 in Patients With Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GenSpera, Inc.
ClinicalTrials.gov Identifier:
NCT01056029
First received: January 25, 2010
Last updated: February 16, 2014
Last verified: November 2012

January 25, 2010
February 16, 2014
January 2010
December 2012   (final data collection date for primary outcome measure)
  • Determine the MTD and DLT(s) of G-202 administered by intravenous infusion daily for 3 consecutive days on a 28-day cycle in patients with advanced solid tumors. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Establish the recommended dose of G-202 to be used in Phase II studies. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Determine the pharmacokinetics of G-202 administered by intravenous infusion daily for 3 consecutive days on a 28-day cycle in patients with advanced solid tumors. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01056029 on ClinicalTrials.gov Archive Site
  • Investigate the safety profile of G-202 administered by intravenous infusion daily for 3 consecutive days on a 28-day cycle in patients with advanced solid tumors. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Document any evidence of anti-tumor activity, including response rate, disease stability, progression-free or overall survival, in response to G-202 administration [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Dose-Escalation Phase 1 Study of G-202 in Patients With Advanced Solid Tumors
An Open_Label, Single-Arm,Dose-Escalation Phase 1 Study of G-202 in Patients With Advanced Solid Tumors

This is an open-label, single-arm, dose-escalation Phase I study to determine the maximum tolerated dose (MTD) of G-202 when administered once daily for 3 consecutive days of a 28-day cycle in patients with advanced solid tumors. G-202 will be administered by intravenous infusion over 1 hour on Days 1, 2 and 3 of each 28-day cycle.

Pro-drug chemotherapy is an approach to cancer treatment that is being investigated as a means to achieve higher concentrations of cytotoxic or biologically active agents at a tumor location while avoiding systemic toxicity. With pro-drug chemotherapy, a relatively non-toxic form of a cytotoxin, the pro-drug, is converted into the active cytotoxic agent at the tumor site or other specific location. G-202 is a thapsigargin pro-drug; it consists of a cytotoxic analog of thapsigargin coupled to a masking peptide which inhibits its biologic activity until proteolytic cleavage at the tumor site. Thapsigargin is a natural product with profound effects on cell viability. Thapsigargin is a non-cell-type specific toxin with documented ability to kill a broad spectrum of cancer cell lines as well as normal endothelial cells, fibroblasts and osteoblasts. It induces a rapid and pronounced increase in the concentration of cytosolic calcium, due to blockade of the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump to which it binds with high affinity. The increase in cytosolic calcium leads to induction of apoptosis and ensuing cell death.

The anti-tumor effect of G-202 in humans with advanced solid tumors is not yet known.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Advanced Solid Tumors
Drug: G-202
Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
Experimental: G-202
Intervention: Drug: G-202
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
August 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically-confirmed malignancy that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective
  • Disease that is measurable and/ or evaluable by RECIST criteria. Patients with prostate cancer require presence of disease on bone scan and/or CT scan and evidence of increasing PSA after standard hormonal therapy
  • ECOG Performance Status ≤ 2
  • Life expectancy estimated to be at least 3 months
  • Acceptable liver function:

    • In the absence of disease involvement in the liver and if bilirubin ≤ 1.5 times institutional upper limit of normal (ULN), AST (SGOT), ALT (SGPT) and GGT may be ≤ 2 times ULN
    • In the presence of disease involvement in the liver and if bilirubin ≤ 1.5 times institutional upper limit of normal (ULN), AST (SGOT), ALT (SGPT) and GGT may be ≤ 5 times ULN
    • Alkaline phosphatase ≤ 2.5 times ULN Patients with bone metastases alkaline phosphatases ≤ 5 times ULN
  • Acceptable renal function:

    • Serum creatinine ≤ 1.5 times ULN, OR
    • Calculated creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)
  • Acceptable hematologic status:

    • Absolute neutrophil count (ANC) ≥ 1500 cells/mm3 (1.5 ×109/L)
    • Platelet count ≥ 100,000 platelet/mm3 (100 ×109/L)
    • Hemoglobin ≥ 9 g/dL
  • Urinalysis with no evidence of proteinuria
  • Acceptable coagulation profile (PT or INR, PTT) < 1.5 times ULN
  • At least 4 weeks since prior chemotherapy or surgery, with recovery to Grade 1 or baseline of significant toxicities felt related to prior drug(s)
  • Women of childbearing potential must have a negative serum pregnancy test at screening.
  • All patients (males and females) of child-bearing potential must agree to use an effective method of birth control
  • Ability to understand and willingness to sign a written informed consent document
  • Patients with prostate cancer must continue androgen deprivation therapy with LHRH agonists

Exclusion Criteria:

  • Documentation of keratosis follicularis, also known as Darier or Darier-White disease
  • Known hypersensitivity to any study drug component, including thapsigargin derivatives, Polysorbate 20, or propylene glycol
  • Patients with known and untreated brain metastases. Patients with brain metastases that have been treated and demonstrated to be clinically stable for at least 30 days may be enrolled onto the study
  • Patients with a family history of coagulopathy or patients with DVT or pulmonary embolus within the last 6 months
  • Patients taking anti-coagulants that include Coumadin or low molecular weight heparin
  • Patients with pre-existing cardiac conditions:

    • Prior documented myocardial infarction within the last 6 months
    • Pre-existing cardiac failure (NYHA class III-IV)
    • Atrial fibrillation on anti-coagulants
    • Unstable angina
    • Severe valvulopathy
    • Cardiac angioplasty or stenting within the last 6 months
  • Use or requirement for use of inhibitors or inducers of cytochrome isoenzymes
  • Corrected QTc prolongation value, calculated using Bazett's formula (QTcB = QT/RR ½), > 450 msec
  • Pregnant or lactating females
  • Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study
  • Active uncontrolled infection, including known history of AIDS or hepatitis B or C
  • Any psychological, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule
  • Concurrently receiving any other investigational agents while on study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01056029
G-202-001
No
GenSpera, Inc.
GenSpera, Inc.
Not Provided
Principal Investigator: George Wilding, M.D University of Wisconsin, Madison
Principal Investigator: Michael Carducci, M.D. The Johns Hopkins University School of Medicine
Principal Investigator: Devalingam Mahalingam, MD University of Texas, Health Science Center,Cancer Therapy and Research Center
GenSpera, Inc.
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP